What went horribly wrong in a London clinical trial?

Scientist

Volumn 20, Issue 5, 2006, Pages 14-

  Colaco, Camilo ^a  

^a ImmunoBiology Limited   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33646483344     PISSN: 08903670     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (8)

1. A. McCook, "UK drug trial effects were 'unpredicted'," The Scientist Daily News, April 6, 2005; www.the-scientist.com/news/ display/23275/
2. "Investigations into adverse incidents during the clinical trials of TGN1412," www.mhra.gov.uk
3. H. Hour-Jordan and J.A. Bluestone, "CD28 Function: A balance of costimulatory and regulatory signals," J Clin Immunol, 22:1-7, 2002.
4. E. J. Evans et al., "Crystal structure of a soluble CD28-Fab complex," Nat Immunol, 6:271-9, 2005.
5. D. Abramowicz et al., "Release of tumour necrosis factor, interleukin-2 and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients," Transplantation, 47:606-8, 1988.
6. L. Chatenoud et al., "In vivo cell activation following OKT3 administration," Transplantation, 49:697-702, 1990.
7. P.A. Carpenter et al., "Non-Fc-receptor binding humanized anti-CD3 antibodies induce apoptosis of activated human T-cells," J Immunol, 165:6205-13, 2000.
8. K.C. Harold et al., "Activation of human T cells by FcR non-binding anti-CD3 mAb, hOKT3γ1 (Ala-Ala)." J Clin Invest, 111:409-18, 2003.